<DOC>
	<DOCNO>NCT01624025</DOCNO>
	<brief_summary>A salvage treatment combination docetaxel epirubicin patient unresectable , metastatic gastric cancer fluoropyrimidine failure : A HER2 status-based study</brief_summary>
	<brief_title>A Comparative Study Salvage Treatment With Combination Docetaxel Epirubicin</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Histologically confirm metastatic , recurrent AGC 2 . Previous use fluoropyrimidine palliative chemotherapy . Concurrent use platinum permit . Patient recur disease within 6 month end adjuvant therapy participate trial . 3 . Documented HER2 expression status . 4 . Radiologically proven progression disease . 5 . Age &gt; 20 year 6 . ECOG PS 0 2 7 . Life expectancy 3 month 8 . Adequate organ function treatment include liver , kidney bone marrow ( absolute neutrophil count ( ANC ) ≥ 1,500/ul , platelet ≥ 100,000/ul , AST/ALT ≤ 2.5 x ULN , ≤ 5.0 x ULN liver involvement , Total serum bilirubin ≤ 2.0 mg/dL ) 9 . Written inform consent 1 . Prior administration taxane anthracycline palliative chemotherapy . If agent use adjuvant neoadjuvant aim , least 6 month pass . 2 . Uncontrolled medical comorbidities Congestive heart failure ( NYHA class III IV ) Recent ( within 6 month ) unstable angina myocardial infarct Clinically significant cardiac arrhythmia LVEF &lt; 45 % Liver cirrhosis ( ChildPugh class B C ) Interstitial pneumonia Psychiatric illness/social situation would limit compliance study requirement 3 . Active CNS metastasis controllable radiation steroid 4 . Concurrent administration systemic chemotherapy radiotherapy . Palliative radiotherapy pain control 2 week ago acceptable . 5 . Pregnant lactating woman . 6 . Peripheral neuropathy G3~4 . 7 . Metachronous malignancy adequately treat CIN uterine cervix , basal cell squamous cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>AGC , second-line , docetaxel , epirubicin</keyword>
</DOC>